Praxis Precision Medicines, Inc.
PRAX
Rank in Stocks
#2760
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Share Price
$244.57
Last synced: 2026-10-16
Market Cap
$6.83B
Change (1 day)
-1.48%
Change (1 year)
28.73%
Country
US
Trade Praxis Precision Medicines, Inc. (PRAX)
Category
Healthcare
EPS for Praxis Precision Medicines, Inc. (PRAX)
EPS as of June 2026 TTM: $-12.95
According to Praxis Precision Medicines, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-12.95. At the end of 2023 the company had a EPS of $-18.69 a decrease compared to its 2022 EPS that were of $-69.33.
EPS history for Praxis Precision Medicines, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-12.95 | 26.84% |
| 2024 | $-10.21 | -45.37% |
| 2023 | $-18.69 | -73.04% |
| 2022 | $-69.33 | 17.59% |
| 2021 | $-58.96 | -43.09% |
| 2020 | $-103.61 | -70.25% |
| 2019 | $-348.24 | 13.53% |
| 2018 | $-306.73 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -233.75% |
US
|
|
| $-7.98 | -38.38% |
US
|
|
| $-5.29 | -59.15% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -314.21% |
NL
|
